Rocket Pharmaceuticals (RCKT) Non-Current Assets (2014 - 2026)

Rocket Pharmaceuticals has disclosed Non-Current Assets across 13 years of filings, most recently posting $135.6 million for Q1 2026.

• Non-Current Assets for Q1 2026 came in at $135.6 million, down 7.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $557.5 million (down 7.35% YoY), and the FY2025 annual result was $137.7 million, down 7.89% from the prior year.
• Non-Current Assets came in at $135.6 million for Q1 2026 at Rocket Pharmaceuticals, down from $137.7 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $188.1 million in Q4 2023 to a low of $106.1 million in Q2 2022.
• The 5-year median for Non-Current Assets is $149.5 million (2024), against an average of $146.2 million.
• Across the five-year window, Non-Current Assets jumped 78.87% in 2022 and fell 20.52% in 2024, its largest moves.
• Rocket Pharmaceuticals' Non-Current Assets stood at $187.7 million in 2022, then increased by 0.2% to $188.1 million in 2023, then dropped by 20.52% to $149.5 million in 2024, then declined by 7.89% to $137.7 million in 2025, then slipped by 1.55% to $135.6 million in 2026.
• The last three Non-Current Assets figures came in at $135.6 million (Q1 2026), $137.7 million (Q4 2025), and $140.4 million (Q3 2025), per Business Quant data.